{
  "report_rows": [
    {
      "kpi": "Total revenue (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$1.31B vs. cons $1.30B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "U.S. revenue / new-patient-start narrative (Q2'26)",
      "prediction": "IN-LINE",
      "answer": "pred ~$938M (+11.5%) vs. cons ~$938M (+11.5%)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP EPS (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$0.64 vs. cons $0.61",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 revenue guide",
      "prediction": "BETTER",
      "answer": "guide raised/floor-lifted to ~$5.20\u20135.28B vs. cons ~$5.22B (FY26)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY26 gross margin guide",
      "prediction": "BETTER",
      "answer": "guide ~64%+ vs. cons/prior 63\u201364% (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 non-GAAP operating margin guide",
      "prediction": "BETTER",
      "answer": "guide ~23.5\u201324% vs. cons/prior 23\u201323.5% (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "T2 non-insulin commercial covered lives commentary",
      "prediction": "BETTER",
      "answer": "guide >7M lives by YE vs. ~5\u20136M current (FY26)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.5,
  "day5_path": "FADE",
  "day5_rationale": "Base case is a modest rev/EPS beat plus a margin-guide raise, good for a +3% pop. But with FY revenue guide only marginally lifted and H1 revenue absorbing the beat, the implied H2 (out-period) growth is unchanged-to-conservative, so Street revenue estimates don't ratchet meaningfully higher. With the stock already up ~13% YTD and near post-Investor-Day/ADA highs (high bar), and the persistent 'U.S. starts only close-to-a-record' overhang, the initial move partially fades over 5 days; buyback support keeps it from fully round-tripping.",
  "day5_confidence": "LOW"
}